GTEx SalivaryGland 20-29 vs 60-69 Down (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GTEx SalivaryGland 20-29 vs 60-69 Down.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GTEx SalivaryGland 20-29 vs 60-69 Down.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GTEx SalivaryGland 20-29 vs 60-69 Down.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GTEx SalivaryGland 20-29 vs 60-69 Down.

Results found

Linked to

 

Label

Description

 

Gene

protein kinase Y-linked (pseudogene)

Gene

taxilin gamma Y-linked (pseudogene)

Gene

urothelial cancer associated 1

Gene

lung cancer associated transcript 1

Gene

fer-1 like family member 4 (pseudogene)

Gene

ribosomal protein SA pseudogene 52

Gene

HOXC13 antisense RNA

Gene

KRTAP5-1/KRTAP5-2 antisense RNA 1

Gene

MT-ND1 pseudogene 23

Gene

long intergenic non-protein coding RNA 858

  • Gene

    protein kinase Y-linked (pseudogene)


  • Gene

    taxilin gamma Y-linked (pseudogene)


  • Gene

    urothelial cancer associated 1


  • Gene

    lung cancer associated transcript 1


  • Gene

    fer-1 like family member 4 (pseudogene)


  • Gene

    ribosomal protein SA pseudogene 52


  • Gene

    HOXC13 antisense RNA


  • Gene

    KRTAP5-1/KRTAP5-2 antisense RNA 1


  • Gene

    MT-ND1 pseudogene 23


  • Gene

    long intergenic non-protein coding RNA 858

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.